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In this  article,  we  describe  the  6 HCV  Genotyping  9G test  and  its evaluation  by  using  clinical  samples  and
plasmid  DNA standards.  In tests  with 981  plasmid  DNA  standards,  the  6 HCV  Genotyping  9G  test  showed
higher  than 92.5%  sensitivity  and  99.4%  speciﬁcity.  The  6 HCV  Genotyping  9G  test  was  compared  with
the  VERSANT  HCV  Genotype  2.0 assay  (LiPA  2.0)  for  detection  and  discrimination  of  HCV  genotypes  in
clinical  samples.  The  results  of  both  tests  were  veriﬁed  by genomic  sequencing.  The  6 HCV  Genotyping  9G
test demonstrated  a 100%  agreement  with  the  sequencing  results,  which  was  higher  than  LiPA 2.0.  Thesecv
CV genotyping
G DNA technology
iPA 2.0
results  indicate  that  the  6 HCV  Genotyping  9G  test  can be  a reliable,  sensitive,  and  accurate  diagnostic
tool  for the  correct  identiﬁcation  of  HCV  genotypes  in clinical  specimens.  6 HCV  Genotyping  9G  test  can
genotype  six  HCV  types  in  1 PCR  in  30 min  after  PCR  ampliﬁcation.  The  6  HCV Genotyping  9G test,  thus
provide  critical  information  to physicians  and  assist  them  to  apply  accurate  drug regimen  for  the  effective
ublis
iver cirrhosis
epatocellular carcinoma
hepatitis  C  treatment.
©  2016  The  Authors.  P
. Introduction
Hepatitis C is a liver disease caused by the hepatitis C virus
HCV). Globally, 150 million people have chronic HCV infection. An
stimated 700,000 people die each year from hepatitis C-related
iver diseases including cirrhosis, hepatocellular carcinoma (HCC)
nd liver failure (WHO  guidelines, 2016). The morbidity and mor-
ality attributable to HCV infection continue to increase (Lavanchy,
011). The treatment of HCV infection has become more compli-
ated due to various genotypes and subtypes of HCV.
HCV is classiﬁed into seven genotypes, 67 conﬁrmed and 20 pro-
isional subtypes with distinct patterns of geographic distribution
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(Smith et al., 2014). Globally, HCV 1 is the most common (46.2%),
followed by HCV 3 (30.1%), HCV 2 (9.1%), HCV 4 (8.3%), HCV 6 (5.4%),
and HCV 5 (0.8%) (Messina et al., 2015). However, among Asian
countries, the distribution and sub-typical composition of HCV6 are
signiﬁcantly different from overall global ratio. For example, HCV6a
(24%) and HCV6n (39%) are predominant in Vietnam and Myanmar,
respectively (Pham et al., 2011; Lwin et al., 2007). In Thai patients
HCV6f is the most common HCV6 subtype (56%), followed by sub-
types 6n (22%), and 6i (11%) (Akkarathamrongsin et al., 2010). A
proper antiviral treatment can cure the HCV infection (Li and Lo,
2015). However, the knowledge about HCV genotype and subgeno-
type is crucial for the appropriate treatment (Wasitthankasem et al.,
2015). It is essential to note that according to the recent recom-
mendations by European Association for the Study of the Liver
(EASL), the treatment of HCV infection signiﬁcantly depends on
particular HCV genotype or sub-genotype (EASL, 2015). The 2016
WHO guidelines for the screening, care, and treatment of patients
with chronic HCV infection recommend the identiﬁcation of HCV
genotypes for the choice of the precise treatment regimen (WHO
guidelines, 2016).
Currently, treatment of HCV has made signiﬁcant advances with
the help of drugs such as pegylated interferon (PegIFN)-,  ribavirin,
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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nd the direct-acting antivirals such as sofosbuvir, simeprevir, ledi-
asvir, ombitasvir, dasabuvir (Mishra et al., 2015). However, the
hoice of medicine or the combination of drugs and the duration
f treatment are different for HCV genotypes 1a, 1b, 2, 3, 4, 5 and
 (EASL 2015). Therefore, for accurate treatment of hepatitis C, it
s imperative to detect and discriminate the crucial HCV genotypes
uch as 1a, 1b, 2, 3, 4, and 6 by using simple and accurate detection
ethod.
Sequence analysis of speciﬁc regions such as NS5, core, E1, and
′ untranslated region (5′UTR) is a gold standard for HCV geno-
yping (Firdaus et al., 2015). However, it is a time-consuming
ethod, expensive, and requires highly trained professional to pro-
ess the samples. Alternative nucleic acid tests such as real-time
CR (Hawkins et al., 1997; Beld et al., 2002), restriction fragment
ength polymorphism (Filippo et al., 2012), heteroduplex mobility
nalysis (White et al., 2000), and line-probe assay (Cai et al., 2013)
re rapid HCV typing methods. The needs for specialized and expen-
ive instruments have limited the applications of these methods in
eveloping countries. The Versant HCV 2.0 assay (line probe assay
LiPA] 2.0), Abbott Realtime HCV Genotype II assay, and Trugene
ssay are widely used commercial assays for HCV genotyping. A
ecent report on the comparison of Trugene assay, LiPA 2.0, and
equencing indicate that these tests can fail to differentiate HCV
ubtypes 1a and 1b, which can lead to critical errors in clinical prac-
ice for correct use of directly acting antiviral agents (Chueca et al.,
016). Furthermore, the LiPA 2.0 assay and the Abbott Realtime HCV
enotype II assay have limitations in identifying HCV genotype 6
Yang et al., 2014) and are expensive. Thus, for the implementa-
ion of a strict treatment regime in the management of hepatitis C,
here is a need to ﬁnd an inexpensive genotyping test that is rapid,
imple, and precise.
In this study, 981 standard plasmid samples were used to evalu-
te the performance of 6 HCV Genotyping 9G test. All samples were
ested under blinded codes. The performance of 6 HCV Genotyping
G test was also evaluated by comparing it with the commercial
ERSANT HCV Genotype 2.0 assay (LiPA 2.0) (Siemens Healthcare
mbH, Erlangen, Germany) and HCV sequencing for detection of
ix HCV genotypes 1a, 1b, 2, 3, 4, and 6 in the serum samples. The
rinciple of 6 HCV Genotyping 9G test includes viral RNA isola-
ion, complementary DNA (cDNA) synthesis, PCR ampliﬁcation, and
etection of PCR amplicons. The cDNA synthesis and PCR ampliﬁ-
ation are done simultaneously in single PCR tube by using RT-PCR.
he 6 HCV Genotyping 9G test is a lateral ﬂow strip membrane
ssay, wherein, the required 9G membranes are obtained by fol-
owing the reported 9G technology (Song et al., 2013). The ssDNA
ligonucleotide probes corresponding to the respective HCV geno-
ypes are immobilized on the 9G membranes at speciﬁc positions.
he immobilized probes hybridize with the complementary Cy5
abeled ssDNAs in the PCR product and allow the discrimination of
ix HCV genotypes. It is the ﬁrst report of its kind to evaluate the
erformance of 6 HCV Genotyping 9G test and its comparison with
he commercial HCV genotyping test. The 6 HCV Genotyping 9G test
able 1
oncentration dependent distribution of standard samples used in 6 HCV Genotyping 9G
Copies/test HCV genotypes 
1a 1b 2 3 4 
1 × 106 5 5 5 5 5 
1000  5 5 5 5 5 
50  10 10 10 10 10 
10  10 10 10 10 10 
5  24 24 24 24 24 
2.5  24 24 24 24 24 
1  24 24 24 24 24 
Total  102 102 102 102 102 
C: negative control samples containing no HCV standard DNA.ogical Methods 239 (2017) 1–8
is designed to provide the necessary information to physicians by
accurate detection of six HCV genotypes in 30 min  after PCR. Thus,
the 6 HCV Genotyping 9G test can enable doctors to select the most
effective treatment regimen as per the EASL recommendations for
hepatitis C management.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich Chemicals,
Korea. The oligonucleotides were purchased from Bioneer, Korea.
Glass ﬁber membrane (2.5 × 7.5 cm)  was  obtained from Whatman,
Springﬁeld, UK. All washing solvents for the substrates are of HPLC
grade from SK Chemicals, Korea. Ultrapure water (18 M /cm) was
obtained from a Milli-Q puriﬁcation system (Millipore). Oligonu-
cleotides were lined using dispenser (BioDot Technologies, Inc.,
2852 Alton Pkwy, Irvine, CA 92606, USA). Hybridization was done
at 25
◦
C. The ﬂuorescence intensities were recorded on the BMT
ReaderTM, Biometrix Technology Inc., South Korea. VERSANT HCV
Genotype 2.0 assay (LiPA 2.0) (Siemens Healthcare GmbH, Erlangen,
Germany) kit was  used as a standard commercial product.
2.2. Composition of different solutions used for 6 HCV genotyping
9G test
a) Hybridization buffers (pH = 7.4): 20% Formamide, 0.25% Triton
X-100, 6x SSC; b) Washing buffer solution (pH = 7.4): 20% For-
mamide, 0.25% Triton X-100, 6x SSC.
2.3. Standard DNA samples
The cDNA standard samples (plasmid DNAs) containing cor-
responding 300-bp sequences of the 5′UTR of HCV RNA were
obtained from Bioneer Inc., Daejeon, Korea. The plasmid cDNA
sequences were unique to the HCV genotypes 1a, 1b, 2, 3, 4, 6a, 6f,
6i, and 6n. Plasmid standard samples (n = 981) were used for the
test under the blinded codes. All standard samples were diluted
with Tris-elution buffer utilized in the regular extraction kits
used for clinical specimens. Thus, the process of evaluation by
using clinical samples was  mimicked in the 6 HCV Genotyping
9G test with plasmid cDNA standard samples. The 981 samples
were separated in eight different categories as 1 × 106 copies/test
(7.5 × 106 copies/mL), 1000 copies/test (7.5 × 103 copies/mL),
50 copies/test (375 copies/mL), 10 copies/test (75 copies/mL),
5 copies/test (38 copies/mL), 2.5 copies/test (19 copies/mL), 1
copy/test (7.5 copies/mL), and 0 copy/test (negative samples).
Table 1 depicts the distribution of 981 standard samples corre-
sponding to the HCV genotypes 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and 6n
in eight concentration categories. All samples were tested under
blinded codes. PCR was  performed on plasmid cDNA samples by
 Test.
Total
6a 6f 6i 6n NC
5 5 5 5 9 54
5 5 5 5 9 54
10 10 10 10 9 99
10 10 10 10 9 99
24 24 24 24 9 225
24 24 24 24 9 225
24 24 24 24 9 225
102 102 102 102 63 981
W.  Chantratita et al. / Journal of Virological Methods 239 (2017) 1–8 3
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.4. Clinical samples
A total of 98 patients serum samples were used in this study.
3/98 samples were from patients known to be infected with the
CV. In the group of 98 serum samples, 35 were from HCV nega-
ive patients. All samples had been previously genotyped by LiPA
.0 according to the manufacturer’s instructions. The HCV RNA
xtraction was performed on the NucliSENS easyMAG (bioMérieux,
oxtel, Netherlands), which automatically extract the nucleic acids
rom the clinical samples. 200 L of plasma was added to the lysis
uffer followed by 10 min  incubation at room temperature. Mag-
etic silica particles were used for nucleic acid binding for 10 min
t room temperature. Silica particles were washed with different
uffers. HCV RNA was eluted in 50 L of Tris-elution buffer and
ubsequently transcribed into cDNA by following the protocols of
iPA 2.0 and 6 HCV Genotyping 9G test.
.5. HCV genotyping 9G test
The principle of 6 HCV Genotyping 9G test includes viral RNA
solation, complementary DNA (cDNA) synthesis, PCR ampliﬁca-
ion, and detection of PCR amplicons. The primers in the 6 HCV
enotyping 9G test amplify the 5′UTR for genotyping of six HCV
enotypes. The probes allow the discrimination of HCV genotypes
a, 1b, 2, 3, 4, 6a or 6f, and 6i or 6n at 25 ◦C in less than 30 min  after
CR.
As shown in Fig. 1, the HC (hybridization control) probe, HCV
probe speciﬁc for the detection of HCV) probe, and six other probes
peciﬁc to the HCV genotypes 1a, 1b, 2, 3, 4, and 6, were immobi-
ized on the glass ﬁber membranes to produce the 9G membranes
ccording to the recently reported method (Song et al., 2013). All
robes were selected according to the generalized probe selection
ethod (Nimse et al., 2011). Fig. 1 also depicts the simple experi-
ental protocol of 6 HCV Genotyping 9G test to obtain ﬁnal results.
The HC probe serves as an internal standard for hybridization
ontrol. The HCV probe is used to detect the presence or absencethe experimental protocol of 6 HCV Genotyping 9G Test.
of HCV in the sample. As shown in Fig. 2, when 6 HCV Genotyping
9G test shows three signals corresponding to probes including the
HC, HCV, and 1a or 2 or 3 or 4, a sample is designated as an HCV
1a or 2 or 3 or 4, respectively. The sample is identiﬁed as HCV 1b
if the test shows four signals for probes including HC, HCV, 1a, and
1b, respectively.
When the test shows three signals corresponding to the probes
HC, HCV, and 6, the sample is genotyped as HCV 6a or 6f. Whereas,
if the test shows four signals corresponding to the probes HC, HCV,
1a, and 6, the sample is genotyped as HCV 6i or 6n. When, 6 HCV
Genotyping 9G test shows two  signals corresponding to the HC and
HCV probes, the sample is identiﬁed to contain the HCV genotype
other than the HCV 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and 6n. However, for an
HCV-negative sample, the test shows only one signal corresponding
to the HC probe.
The process of 6 HCV Genotyping 9G test after completion of
cDNA synthesis followed by PCR ampliﬁcation is brieﬂy discussed
here. 110 L of hybridization solution was  added to each PCR tube
containing 20 L PCR product. Then, 110 L of this mixture was
loaded into the sample port of the 6 HCV Genotyping 9G test and
allowed to stand for 20 min  at 25 ◦C. After 20 min, 200 L of washing
solution was loaded into the washing port of the 6 HCV Genotyp-
ing 9G test and allowed to stand for 8 min at 25 ◦C. After 8 min,
each 6 HCV Genotyping 9G test strips was scanned on the BMT
ReaderTM, (Biometrix Technology Inc. Chuncheon, South Korea) to
obtain the ﬁnal results as shown in Fig. 2. Table 2 and Table 3 sum-
marize the results of the 6 HCV Genotyping 9G test on standard
samples. Table 4 and Table 5 summarize the comparative results
on clinical samples obtained by 6 HCV Genotyping 9G test, LiPA
2.0, and sequencing.
2.6. LiPA 2.0
LiPA 2.0 is a reverse hybridization line probe assay. Viral RNA
was puriﬁed using a QIAamp viral RNA minikit (Qiagen, Hilden,
Germany) and was subjected to reverse transcription-PCR (RT-PCR)
with a Versant HCV ampliﬁcation 2.0 kit (manufactured by Inno-
genetics, Ghent, Belgium, for Siemens, Tarrytown, NY, USA). The
240-bp 5′UTR and 270-bp core fragments were co-ampliﬁed to
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Table  2
Results of 6 HCV Genotyping 9G Test on 981 standard samples at different concentrations.
Copies/test Variant TP TN FP FN Total % Sensitivity (95% CI) % Speciﬁcity (95% CI)
1 × 106 HCV± 45 9 0 0 54 100.0 (92.1–100.0) 100.0 (66.3–100.0)
1a  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
1b  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
2  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
3  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
4  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6a  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6f  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6i  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6n  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
1000  HCV± 45 9 0 0 54 100.0 (92.1–100.0) 100.0 (66.3–100.0)
1a  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
1b  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
2  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
3  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
4  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6a  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6f  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6i  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
6n  5 49 0 0 54 100.0 (47.8–100.0) 100.0 (92.8–100.0)
50  HCV± 90 9 0 0 99 100.0 (96.0−100.0) 100.0 (66.4–100.0)
1a  10 88 1 0 99 100.0 (69.2–100.0) 98.9 (93.2–100.0)
1b  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
2  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
3  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
4  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6a  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6f  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6i  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6n  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
10  HCV± 90 9 0 0 99 100.0 (96.0−100.0) 100.0 (66.4–100.0)
1a  10 88 1 0 99 100.0 (69.2–100.0) 98.8 (93.2–100.0)
1b  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
2  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
3  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
4  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6a  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6f  10 88 1 0 99 100.0 (69.2–100.0) 98.8 (93.2–100.0)
6i  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
6n  10 89 0 0 99 100.0 (69.2–100.0) 100.0 (95.9–100.0)
5  HCV± 210 9 0 6 225 97.2 (94.1–98.9) 100.0 (66.4–100.0)
1a  24 200 1 0 225 100.0 (85.7–100.0) 99.5 (97.3–100.0)
1b  21 200 1 3 225 87.5 (67.6–97.3) 99.5 (97.2–100.0)
2  24 201 0 0 225 100.0 (85.8–100.0) 100.0 (98.2–100.0)
3  22 201 0 2 225 91.7 (73.0−98.9) 100.0 (98.2–100.0)
4  20 199 2 4 225 83.3 (62.6–95.3) 99.0 (96.5–99.8)
6a  21 201 0 3 225 87.5 (67.6–97.3) 100.0 (98.1–100.0)
6f  22 201 0 2 225 91.7 (73.0−98.9) 100.0 (98.2–100.0)
6i  20 201 0 4 225 83.3 (62.6–95.2) 100.0 (98.1–100.0)
6n  22 199 2 2 225 91.6 (73.0−98.9) 99.0 (96.5–99.8)
2.5  HCV± 178 9 0 38 225 82.4 (76.7–87.2) 77.8(39.9–97.1)
1a  18 201 0 6 225 75.0 (53.3–90.2) 100.0 (98.2–100.0)
1b  16 201 0 8 225 66.6 (44.6–84.3) 100.0 (98.2–100.0)
2  15 197 4 9 225 62.5 (40.5–81.2) 98.0 (94.9–99.4)
3  16 199 2 8 225 66.6 (44.6–84.3) 99.0 (96.4–99.8)
4  13 200 1 11 225 54.1 (32.8–74.4) 99.5 (97.2–99.9)
6a  14 201 0 10 225 58.3 (36.6–77.8) 100.0 (98.1–100.0)
6f  13 201 0 11 225 54.2 (32.8–74.4) 100.0 (98.1–100.0)
6i  14 197 4 10 225 58.3 (36.6–77.8) 98.0 (94.9–99.4)
6n  14 199 2 10 225 58.3 (36.6–77.8) 99.0 (96.4–99.8)
1  HCV± 166 9 0 50 225 76.9 (70.7–82.3) 100.0 (66.4–100.0)
1a  13 200 1 11 225 54.1 (32.8–74.4) 99.5 (97.2–99.9)
1b  10 198 3 14 225 41.6 (22.1–63.3) 98.5 (95.7–99.6)
2  12 199 2 12 225 50.0 (29.1–70.8) 99.0 (96.4–99.8)
3  10 201 0 14 225 41.6 (22.1–63.3) 100.0 (98.2–100.0)
4  13 201 0 11 225 54.1 (32.8–74.4) 100.0 (98.1–100.0)
6a  4 200 1 20 225 16.6 (4.7–37.3) 99.5 (97.2–99.9)
6f  5 200 1 19 225 20.8 (7.1–42.1) 99.5 (97.2–99.9)
6i  6 199 2 18 225 25.0 (9.7–46.7) 99.0 (96.4–99.8)
6n  5 200 1 19 225 20.8 (7.1–42.1) 99.5 (97.2–99.9)
TP: true positive, TN: true negative, FP: false positive, FN: false negative.
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Fig. 2. The ﬁnal result for HCV genotypes A) 1a, B) 1b, C) 2, D) 3, E) 4, F) 6a or 6f, G) 6i or 6n, and H) HCV negative samples in 6 HCV Genotyping 9G Test.
Table 3
Overall sensitivity and speciﬁcity of the 6 HCV Genotyping 9G Test on 531 standard samples with concentrations of 5 copies/test ∼ 1 × 106 copies/test.
Variant TP TN FP FN % Sensitivity (95% CI) % Speciﬁcity (95% CI)
HCV± 480 45 0 6 98.7 (97.3–99.5) 100.0 (92.1–100.0)
1a  54 474 3 0 100.0 (93.4–100.0) 99.4 (98.2–99.8)
1b  51 476 1 3 94.4 (84.6–98.8) 99.8 (98.8–99.9)
2  54 477 0 0 100.0 (93.4–100.0) 100.0 (99.2–100.0)
3  52 477 0 2 96.3 (87.2–99.5) 100.0 (99.2–100.0)
4  50 475 2 4 92.5 (82.1–97.9) 99.5 (98.4–99.9)
6a  51 477 0 3 94.4 (84.6–98.8) 100.0 (99.2–100.0)
6f  52 476 1 2 96.3 (87.2–99.5) 99.7 (98.8–99.9)
6i  50 477 0 4 92.6 (82.1–97.9) 100.0 (99.2–100.0)
6n  52 475 2 2 96.3 (87.3–99.5) 99.5 (98.4–99.9)
Table 4
Results of 6 HCV Genotyping 9G Test and LiPA 2.0 assay for 79 samples.
Results of LiPA 2.0 Results of 6 HCV Genotyping 9G Test
1a 1b 2 3 4 6a or 6f 6i or 6n Negative Total
1a 5 5
1b  15 15
2  0 0
3  13 13
4  0 0
4  7
6  (c-l) 11 11
p
t
tNegative 
Total  5 15 0 13 roduce biotinylated PCR product. For the detection of HCV geno-
ypes, a biotinylated PCR product is allowed to hybridize with
he immobilized oligonucleotide probes that are speciﬁc for the35 35
0 4 7 35 795′-UTRs and core regions of the six HCV genotypes. The hybridized
biotinylated DNA PCR product is detected by using the signal
ampliﬁcation technique, which uses alkaline phosphatase-labeled
6 W.  Chantratita et al. / Journal of Virological Methods 239 (2017) 1–8
Table  5
Comparison of 6 HCV Genotyping 9G Test and LiPA 2.0 with the sequencing for 19 discordant samples (HCV genotype is given in parenthesis).
HCV Genotype Sequencing 6 HCV Genotyping 9G Test LiPA 2.0
1a 0 0 0
1b  11 11 (1b) 2 (1a), 9 (6(c-l))
2  0 0 0
3  1 1 (3) 1 (6(c-l))
4  0 0 0
6f  0 0 0
6i  7 7 (6i or 6n) 5 (1b), 2 (1a)
0 
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Total  19 
treptavidin and 5-bromo-4-chloro-3-indolylphosphate (BCIP)-p-
itroblue tetrazolium chromogen. The results were interpreted
ccording to the LiPA 2.0 interpretation chart, where the line pat-
erns and the corresponding genotyping results are listed. Tables 4
nd 5 show the results of the LiPA 2.0 assay in comparison with 6
CV Genotyping 9G test and sequencing.
.7. Sequence analysis
The sequence of ampliﬁed fragment (from clinical samples) was
etermined on Applied Biosystems (ABI) 3730 × L DNA analyzer
Life Technologies Co., Carlsbad, CA, USA). The speciﬁc HCV geno-
ypes were conﬁrmed by comparing the obtained sequences with
he reported sequences on the Basic Local Alignment Search Tool
BLAST) database of NCBI. The results of the sequencing analysis
re shown in Tables 4 and 5.
. Results
.1. Standard samples
As shown in Tables 1 and 2, 981-blinded samples were tested to
valuate the 6 HCV Genotyping 9G test for the accurate detection
nd genotyping of HCV strains. The PCR ampliﬁcation to obtain the
CV DNA amplicons was performed on each of the 981 samples. Out
f 981 samples, 54 samples each was in the concentration category
f 1 × 106 copies/test and 1000 copies/test. Out of these 54 samples,
ine samples were negative and remaining 45 samples were further
ivided into ﬁve samples each of HCV genotypes 1a, 1b, 2, 3, 4, 6a,
f, 6i, and 6n, respectively. Similarly, there were 99 samples each in
he concentration category of 50 copies/test and 10 copies/test. Out
f these 99 samples, nine samples were negative, and remaining 90
amples were further divided into ten samples each of HCV geno-
ypes 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and 6n, respectively. There were 225
amples each in the concentration category of 5 copies/test and 2.5
opies/test and 1 copy/test. Out of these 225 samples, nine samples
ere negative, and remaining 116 samples were further divided
nto 24 samples each of HCV genotypes 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and
n, respectively. Hence, out of 981 samples, 63 samples were true
CV negative and 918 samples were true HCV positive.
The data presented in Table 2 shows the sensitivity and speci-
city of each probe at different concentrations of HCV cDNA in
he samples. The 6 HCV Genotyping 9G test correctly detected 918
amples as true positive (with HCV cDNA) and 63 samples as true
egative (without HCV cDNA) on the HCV line irrespective of the
oncentration of a cDNA in the sample. The HCV probe showed
lmost 100% sensitivity and speciﬁcity, respectively. However, as
hown in Table 2, the sensitivity of the probes corresponding to
he HCV genotypes 1a, 1b, 2, 3, 4, 6a, were signiﬁcantly lower
or the samples containing HCV cDNA with concentrations of 2.5
opies/test (54.1–82.4%) and 1 copy/test (16.6–76.9%). For these
amples, the sensitivity of the six probes were in the range of
0–75%. However, the samples containing 5 copies/test of HCV0
19
cDNA all probes demonstrated the sensitivity and speciﬁcity of
83–100% and 99–100%, respectively. Therefore, the limit of detec-
tion (LOD) of the 6 HCV Genotyping 9G test for the detection and
discrimination of HCV genotypes 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and 6n
were decided to be 5 copies/test (38 copies/mL). Thus, the LOD
of the 6 HCV Genotyping 9G test is much lower than the LOD
(4810 IU/mL) reported for the commercial assays (Nadarajah et al.,
2007).
The LOD being set to 5 copies/test, the data on the 531 standard
plasmid samples was  used for the determination of the overall sen-
sitivity and speciﬁcity of the 6 HCV Genotyping 9G test as shown
in Table 3. Out of 531 samples, 486 samples (54 samples per HCV
genotypes 1a, 1b, 2, 3, 4, 6a, 6f, 6i, and 6n) were true HCV positive
and 45 samples were true HCV negative. All samples were correctly
detected by each probe corresponding to the HCV genotypes 1a, 1b,
2, 3, 4, 6a, 6f, 6i, and 6n, respectively. The probe corresponding to
the HCV genotype 1a successfully identiﬁed the HCV 1a in all 54
HCV true positive samples. However, 3/477 samples that did not
have any HCV 1a cDNA in them were falsely detected as HCV 1a,
false positive results. Out or 54 true positive samples and 477 true
negative samples for HCV 1b, the probe for HCV 1b showed one false
positive result and three false negative result, respectively. Out of
54 true positive samples for each of the HCV type 2, 3, 4, and 6a, 6f,
6i, and 6n, the probes corresponding to respective HCV genotypes
demonstrated 0, 2, 4, 3, 2, 4, and 2 false negative results, respec-
tively. However, the false negative rate for probes corresponding
to the HCV type 2, 3, 4, and 6a, 6f, 6i, and 6n was low.
The data presented in Table 3 shows the sensitivity and speci-
ﬁcity of each probe used in the 6 HCV Genotyping 9G test for the
detection of HCV genotypes in the standard plasmid DNA samples.
The sensitivity of all six probes for detection of HCV genotypes in
the standard samples were in the range 92.6-100%. The speciﬁcity
of all six probes was  higher than 99%. The sensitivity and speciﬁcity
of the probes were in the range 83.3-100% and 77.8%-100%, respec-
tively, for samples containing more than 5 copies/test of HCV cDNA.
These results indicate that 6 HCV Genotyping 9G test can be used
effectively for the detection and genotyping of the HCV in clinical
samples.
3.2. Clinical samples
As shown in Table 4, 6 HCV Genotyping 9G test and LiPA 2.0
assay showed concordance in the detection of HCV genotypes in
79/98 clinical samples and discordance in the detection of 19/98
samples. Both tests showed 80.6% agreement and 19.4% discor-
dance in the results for the detection of HCV genotypes. As shown
in Table 4, both tests clearly identiﬁed 35 HCV negative samples as
HCV negative.
Out of 44 HCV positive samples with the concordance of results
in both tests, ﬁve (11.4%), 15 (34.1%), 13 (29.5%), and 11 (25.0%)
samples, were HCV genotypes 1a, 1b, 3, and 6, respectively. LiPA
2.0 assay identiﬁed eleven HCV6 genotype samples as HCV 6(c-l).
Whereas, 6 HCV Genotyping 9G test identiﬁed 4 (9.1%) and 7 (15.9%)
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ut 11 HCV6 genotype samples as HCV(6a or 6f) and HCV(6i or 6n),
espectively. The 6 HCV Genotyping 9G test can subtype the HCV6
enotype into two categories viz. HCV(6a or 6f) and HCV(6i or 6n).
The 19/98 (19.4%) samples that showed discordance in the
esults of 6 HCV Genotyping 9G test and LiPA 2.0 assay were geno-
yped by sequencing. Table 4 summarizes the comparison of the
esults of sequencing, 6 HCV Genotyping 9G test and LiPA 2.0 assay.
equencing identiﬁed 11 (57.9%), 1 (5.3%), and 7 (36.8%) samples
ut of 19 samples as HCV genotypes 1b, 3, and 6i, respectively. As
hown in Table 5, 6 HCV Genotyping 9G test showed 100% agree-
ent with the results of sequencing for the detection of HCV1b,
CV3, and HCV6i samples. However, LiPA 2.0 assay showed com-
lete disagreement with sequencing analysis. The eleven HCV1b
amples were correctly identiﬁed as HCV1b in 6 HCV Genotyping 9G
est. However, of the eleven HCV1b samples LiPA 2.0 assay falsely
etected two and nine samples as HCV1a and HCV6 (c-l), respec-
ively. An HCV3 sample was designated as HCV6 (c-l) in the LiPA
.0 assay. All of the seven HCV6i samples were detected as HCV(6i
r 6n) in the 6 HCV Genotyping 9G test. However, out seven HCV6i
amples, LiPA 2.0 assay detected 5 and 2 samples as HCV1b and
CV1a, respectively.
These results clearly indicate that, 6 HCV Genotyping 9G test is
uperior over LiPA 2.0 assay for the genotyping of HCV. The over-
ll sensitivity and speciﬁcity of 6 HCV Genotyping 9G test were
00.0% (94.3–100.0% at 95% CI) and 100.0% (90.0–100.0% at 95% CI),
espectively. At the individual subtype level, both the sensitivity
nd speciﬁcity of the 6 HCV Genotyping 9G test were 100%. It was
bserved in this test that the LiPA 2.0 assay has limitations in the
orrect detection and discrimination of the HCV genotypes 1a, 1b,
nd 6. The overall sensitivity and speciﬁcity of LiPA 2.0 assay were
9.8% (56.9–80.7% at 95% CI) and 100.0% (90.0–100.07% at 95% CI),
espectively.
. Discussion
The evaluation of 6 HCV Genotyping 9G test for HCV genotyping
nd subtyping was conducted on 981 blinded standard samples,
ith results indicating more than 92% sensitivity and 99% speci-
city for the detection of HCV genotypes. The results of the 6 HCV
enotyping 9G test on the standard samples clearly indicate that
his test can discriminate the HCV 1a, 1b, 2, 3, 4, and HCV 6 (6a or
f, and 6i or 6n). Essentially, the application of any new test can
e adjudicated based on its performance for the detection of HCV
enotypes in the clinical samples. Thus, 98 clinical samples were
sed in the preliminary clinical evaluation of the 6 HCV Genotyping
G test.
In this study, the commercial LiPA 2.0 assay and sequencing
nalysis were used as the standards for the detection of the HCV
enotypes in the 98 patients serum samples under blinded codes.
he 6 HCV Genotyping 9G test showed 100.0% concordance with
equence analysis in the 19 samples. However, the LiPA 2.0 assay
howed complete discordance with sequence results for the 19
amples that were discordant with 6 HCV Genotyping 9G test.
The limitation of the LiPA 2.0 assay for the correct identiﬁcation
f HCV 1a, 1b, and HCV 6 is reported (Chueca et al., 2016). It was
bserved in this study that the HCV genotypes 1a, 1b, 2, 3, 4, and 6
long with their subtypes have more than 95% sequence homology.
hus, the high percentage of sequence homology is a likely reason
or the discrepancies in the results of LiPA 2.0 assay.
Sequence analysis is considered the gold standard and it is
bserved in this study that the results of 6 HCV Genotyping 9G
est were in 100% agreement with it. It is important to note that
ccording to an earlier report, the 9G membrane technology used
n the 6 HCV Genotyping 9G test enables detection of genomic DNAs
ith a concentration of 38 copies/mL. Moreover, the sensitivity andgical Methods 239 (2017) 1–8 7
speciﬁcity of 6 HCV Genotyping 9G test for the detection of the HCV
genotype viz. 1a, 1b, 2, 3, 4, and 6 (6a or 6f and 6a or 6i) in the
standard plasmid samples with the concentration higher than 38
copies/mL was  over 94% and 99%, respectively. At higher concen-
trations the sensitivity and speciﬁcity of the 6 HCV Genotyping 9G
test is 100.0%.
The correct identiﬁcation of the HCV genotypes in the HCV-
infected patients is critical information for physicians to apply
the proper drug regimen. Therefore, it is vital for the clinical lab-
oratories to use the most accurate method to provide in-depth
information on HCV infection to clinicians for better patient care.
It is important to note that 6 HCV Genotyping 9G test uses single
RT-PCR for the identiﬁcation of HCV genotypes and delivers ﬁnal
results in less than 30 min  at 25 ◦C after PCR.
5. Conclusion
The evaluation of 6 HCV Genotyping 9G test by using 981 stan-
dard samples showed the overall sensitivity and speciﬁcity to be
higher than 92.5% and 99.4%, respectively. The results of evalua-
tion of the 6 HCV Genotyping 9G test indicates that it is a reliable,
sensitive, and accurate diagnostic tool for the detection and geno-
typing HCV genotypes in clinical samples. However, only 15 clinical
samples were used in this study. Therefore, the evaluation of the
6 HCV Genotyping 9G test with a broader range of clinical sam-
ples would be necessary to substantiate the ﬁndings in this report.
The 6 HCV Genotyping 9G test provides valuable information to
physicians by detecting and discrimination the six HCV genotypes
in 30 min after PCR, which is vital information for the choice of
deﬁnitive drug therapy.
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